Interleukin-7 is a well-studied growth factor that is known to help generate and maintain the immune system's memory CD8 T cells, which have the ability to remember the identity of its targets, such as cancer cells or cells that have been taken over by a virus. A paucity of interleukin-7 is believed to limit the survival and persistence of memoryCD8 T cells.
Despite the promise of interleukin-7 as a means to bolster immunity, an optimal treatment regimen has yet to be determined.
In studies in mice, Suresh and his colleagues found that T cell memory is best enhanced when interleukin-7 is administered during a phase of infection when the number of T cells is ramping down.
In the new Wisconsin study, Suresh's group gave interleukin-7 to mice during different stages of a viral infection. They found that by administering interleukin-7 when the number of T cells is in decline, it is possible to increase the number of memory CD8 T cells that remain to stand guard and protect against re-infection.
"The purpose of the immune response is to expand these cells," says Suresh, explaining that T cells act like serial killers, snuffing one infected cell after another until the viral infection is controlled.
During the expansion phase of infection, when the body is generating the most T cells, administration of interleukin-7 seems to have no effect, according to Suresh. But during the contraction phase, memory is increased.
"We tried this in a DNA vaccine and it works," says Suresh. "Even w
'/>"/>
| Contact: Marulasiddappa Suresh sureshm@svm.vetmed.wisc.edu 608-265-9791 University of Wisconsin-Madison Source:Eurekalert |